NH TherAguix SAS : announces the thesis defense of Dr. Paul Rocchi as the first NHT-funded PhD student

View in browser

NH TherAguix, nanomedicine for precision radiotherapy

NH TherAguix announces the thesis defense of Dr. Paul Rocchi

as the rst NHT-funded PhD student

Paul Rocchi together with members of the jury. From left to right: Prof. Stéphane Roux (UTINAM, Besançon), Dr. Tristan Doussineau (NHT, Meylan), Prof. Olivier Tillement (ILM, Lyon), Dr. Paul Rocchi (NHT, Meylan), Dr. François Lux (ILM, Lyon), Prof. Nadine Millot (ICB, D on), Prof. Laurent David (IMP, Lyon), Dr. Nathalie Mignet (UTCBS, Paris)

NH TherAguix ("NHT"), a French clinical biotech specialized in the development of innovative nanomedicine for the treatment of cancer by radiotherapy, is pleased and proud to announce that Mr Paul Rocchi successfully defended his thesis on October 6th, 2022, as the rst CIFRE PhD student of the company. He performed his research and development work at Institut Lumière Matière in Lyon University under the supervision of Prof. Olivier Tillement and Dr. François Lux. During his PhD work he developed in collaboration with Institut des Sciences Analytiques (Lyon) analytical solutions strengthening the analytical portfolio for ne characterization of innovative nanohybrid products including AGuIX®, NHT's leading drug candidate currently tested in clinics. He also contributed to the development of second generation theranostic nanoparticles by establishing their process of fabrication and demonstrating their rst proof-of-concept of

• ciency together with top-level academic partners (Dana Farber Harvard Cancer Center, Boston and Institut de Physique des Deux In nis, Lyon). Paul Rocchi is co-author of seven

peer-reviewed articles and declared inventor of three patents ling applications. The jury

highlighted the quality of the manuscript as well as its defense and warmly congratulated Paul Rocchi for this rich and enriching multidisplinary work. All the NHT team also joins these deserved congratulations and want to warmly thank Paul as well as his supervisors for their kind and productive guidance to him.

Main publications :

Taylor Dispersion Analysis Coupled to Inductively Coupled Plasma-Mass Spectrometry for Ultrasmall Nanoparticle Size Measurement: From Drug Product to Biological Media Studies

Lucie Labied, Paul Rocchi et al, Anal. Chem. 2021, 93, 3, 1254

A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers

Paul Rocchi, Delphine Brichard-Vernos et al, Pharmaceutics 2022, 14, 4, 814

Identi cation of Molecular Fragments in Equilibrium with Polysiloxane Ultrasmall Nanoparticles

Paul Rocchi, Lucie Labied et al, Nanomaterials 2022, 12, 5, 738

About NH TherAguix (www.nhtheraguix.com):

NH TherAguix, headquartered in Meylan (France), is a Biotech clinical development company. Its candidate drug AGuIX® has been developed to increase the effectiveness of radiation therapy that affects 60% of cancer patients. By its radiosensitizing effect, AGuIX® increases the dose difference between the dose of X-rays received by tumors and received by the surrounding healthy tissues. Its clinical effectiveness is based on a nanometric structuring that allows intravenous injection and the combination of three essential properties to ght tumors: target, image and treat. AGuIX® is therefore part of the concept of theranostics, which corresponds to the combination of therapy (radiosensitizing effect) and diagnosis (visible in MRI), and more generally precision medicine.

AGuIX® has rst been extensively tested in various preclinical models and the results published in high impact publications (>80 papers). The innovation is protected by 15 patent families. As of today, the product has been injected in ~100 patients with no safety issues. Results of the First-In-Human Phase 1 trial in brain metastases (NANORAD1, 15 pts/15, France) so far have con rmed the triple effect: targeting, imaging and treatment and doses safety pro le (Verry et al, Science Advances 2020, Verry et al. Radiotherapy & Oncology, 2021). AGuIX® is currently undergoing two Phase 2 randomized trials in brain metastases using either whole brain radiation therapy, (NANORAD2, multicentric, CHUGA Grenoble France) or stereo-radiosurgery,(NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA). In parallel, three other exploratory trials are underway: a Phase 1b-2

trial for pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA), a Phase 1b-2 trial for glioblastoma (NANOGBM, multicentric, Centre Jean Perrin, Clermont Ferrand, France), a Phase 1b trial for advanced cervix cancer (NANOCOL, Institut Gustave Roussy, France).

NH TherAguix was founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix since inception) and Pr. Olivier Tillement (Professor of Chemistry at University of Lyon) after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radiosensitizing effect. Altogether, NH TherAguix raised €29M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova. The management team is composed of Hervé Brailly (Innate Pharma) as Chairman of the board, Olivier de Beaumont as Chief Medical O cer, Frédéric Griolet as Chief Industrialization O cer and Géraldine Le Duc as CEO.

Géraldine Le Duc

CEO & Co-founder

[e-mail]

NH THERAGUIX

29 chemin du Vieux Chêne,

38240 MEYLAN, FRANCE

You received this email because you signed up on our website.

Unsubscribe